4.7 Article

Drug delivery with nanospherical supramolecular cell penetrating peptide-taxol conjugates containing a high drug loading

Journal

JOURNAL OF COLLOID AND INTERFACE SCIENCE
Volume 453, Issue -, Pages 15-20

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.jcis.2015.04.028

Keywords

Self-assembly; Supramolecular nanostructures; Taxol; Drug delivery; Cell penetrating peptide; Self-assembling peptide; Doxorubicin; Cancer therapy

Funding

  1. NSFC [81301311, 81071731, 81372844]
  2. program for Changjiang Scholars and Innovative Research Team in University [IRT13023]
  3. Ph.D. Programs Foundation of Ministry of Education of China [20131202110002]
  4. Tianjin Medical University Cancer Institute and Hospital Foundation of Seed Project [1201]

Ask authors/readers for more resources

Hypothesis: Supramolecular nanostructures via small molecule self-assembly hold great promise for controlled delivery of hydrophobic anticancer drugs. Particularly, taxol has recently been discovered to possess excellent self-assembly property, which may provide new opportunities to develop a new class of functional supramolecular nanomaterials for drug delivery application. Experiments: A cell penetrating peptide (CPP)-taxol conjugate (Taxol-CPP) was designed and synthesized. The self-assembling property of Taxol-CPP was investigated and the resultant nanomaterials were well characterized. Subsequently, the cytotoxicity of the Taxol-CPP after self-assembly against HepG2 cancer cells was evaluated. Findings: It is found that the Taxol-CPP possesses a high drug loading of 26.4% in each molecule, which is able to self-assemble into supramolecular nanospheres. By taking advantages of the self-assembly ability of taxol, Taxol-CPP supramolecular nanospheres with a mean size of around 130 nm can be obtained, composed of only the functional peptide (CPP) and the drug (taxol). Furthermore, we have demonstrated that the Taxol-CPP nanospheres do not compromise the taxol's potency, which can also be utilized as the carriers for co-delivery of another anticancer drug (doxorubicin). (C) 2015 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available